<DOC>
	<DOC>NCT00663169</DOC>
	<brief_summary>This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.</brief_summary>
	<brief_title>Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Gouty</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>score over 50 on the 0100 VAS pain scale acute, confirmed gout flare for no longer than 3 days Treatment with biological antitumor necrosis factor (antiTNF) within the past 3 months Antiinflammatory medication for the treatment of acute gout within the previous 24 hours Pregnant or breastfeeding women Major surgery with high infection risk History of severe allergy to food or drugs History or risk of tuberculosis Active infection Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Arthritis Gouty</keyword>
	<keyword>ACZ885</keyword>
	<keyword>IL1B protein</keyword>
	<keyword>Pain</keyword>
</DOC>